WCN26-2377 RENOPROTECTIVE EFFICACY AND SAFETY PROFILE OF TARGETED-RELEASE BUDESONIDE IN IgA NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Read full text Summarise with VIRAT
Authors: Jeremia Siregar, Angeline Tancherla, Andree Kurniawan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) remains the most common primary glomerulonephritis and a leading cause of kidney failure worldwide, with especially high burden in Asian populations. Despite optimized supportive care, many patients progress to end-stage kidney disease. Targeted-release budesonide (TRF-budesonide), designed to selectively modulate gut-associated immunity, offers a novel approach with reduced systemic corticosteroid exposure. Its impact on clinical outcomes and practice integration requires synthesis.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106185–106185
Publication date
25 March 2026
Language
EN